twelvebees...that is all very naive thinking (no offense). re exclusive license, if ABT announced anything like what you're describing it would make the price tag for an exclusive license go through the roof -- so i think you have the logic backwards on that point. regarding biocurex funding for their research, per the agreement BOCX is not expected to pay for any R&D, marketing, distribution, etc -- so i don't see your point on that one either.
my previous answer does not imply that ABT is trying to "exploit" BOCX...i'm just saying that ABT has ZERO interest in BOCX shareholders. ZERO.
ABT cares about ABT shareholders.